Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We utilise our cutting-edge, exclusive workflow to develop focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q86UV7

UPID:
TRI73_HUMAN

ALTERNATIVE NAMES:
Tripartite motif-containing protein 50B

ALTERNATIVE UPACC:
Q86UV7; Q8N0S3

BACKGROUND:
The Tripartite motif-containing protein 73, with its alternative identity as Tripartite motif-containing protein 50B, is integral to cellular functionality. This protein's architecture, featuring a tripartite motif, indicates its involvement in a broad spectrum of cellular activities. Its designation within the tripartite motif protein family emphasizes its critical role in cellular regulation and homeostasis.

THERAPEUTIC SIGNIFICANCE:
Investigating the functions of Tripartite motif-containing protein 73 holds promise for identifying new therapeutic avenues. As a key player in cellular processes, it represents an intriguing target for drug discovery efforts. The pursuit of understanding its biological roles could pave the way for innovative treatments, highlighting its potential impact on medical science.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.